JP2017510641A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510641A5
JP2017510641A5 JP2017502932A JP2017502932A JP2017510641A5 JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5 JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5
Authority
JP
Japan
Prior art keywords
cancer
nitrogen
independently selected
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510641A (ja
JP6757312B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022841 external-priority patent/WO2015148854A1/en
Publication of JP2017510641A publication Critical patent/JP2017510641A/ja
Publication of JP2017510641A5 publication Critical patent/JP2017510641A5/ja
Application granted granted Critical
Publication of JP6757312B2 publication Critical patent/JP6757312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502932A 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤 Active JP6757312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971023P 2014-03-27 2014-03-27
US61/971,023 2014-03-27
PCT/US2015/022841 WO2015148854A1 (en) 2014-03-27 2015-03-26 Substituted indole mcl-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2017510641A JP2017510641A (ja) 2017-04-13
JP2017510641A5 true JP2017510641A5 (enExample) 2018-05-17
JP6757312B2 JP6757312B2 (ja) 2020-09-16

Family

ID=54196421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502932A Active JP6757312B2 (ja) 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤

Country Status (7)

Country Link
US (3) US10533010B2 (enExample)
EP (1) EP3122353B1 (enExample)
JP (1) JP6757312B2 (enExample)
CN (1) CN106456602B (enExample)
AU (1) AU2015235944B2 (enExample)
CA (1) CA2943815C (enExample)
WO (1) WO2015148854A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148854A1 (en) 2014-03-27 2015-10-01 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CN109153643B (zh) * 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
US20200062738A1 (en) * 2017-04-30 2020-02-27 Development Center For Biotechnology Anti-cancer stemness drugs
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
TWI810220B (zh) 2017-11-17 2023-08-01 德商拜耳廠股份有限公司 經取代之巨環吲哚衍生物
US11478451B1 (en) 2017-11-17 2022-10-25 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096914A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
UY37973A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
CN109988151B (zh) * 2017-12-29 2021-04-23 北京赛特明强医药科技有限公司 一种炔类化合物、制备方法及其应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
CN108251104B (zh) * 2018-02-27 2019-11-05 山东大学 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用
DK3793565T3 (en) * 2018-05-14 2022-03-07 Gilead Sciences Inc Mcl-1-inhibitorer
EP3810573A4 (en) 2018-06-25 2021-12-08 Suzhou Mednes Pharma Tech Co., Ltd. COMPOUNDS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE HEDGEHOG ROUTE
EP3856258B1 (en) * 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
TWI745836B (zh) * 2019-01-18 2021-11-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑製劑的大螺環醚
US12338250B2 (en) 2019-05-17 2025-06-24 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
AU2023389065A1 (en) * 2022-12-06 2025-06-19 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703053A (en) 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
GB8531612D0 (en) 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
DE4128015A1 (de) 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5436264A (en) * 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
JP3739432B2 (ja) 1994-02-25 2006-01-25 ダイセル化学工業株式会社 オゾン開裂反応
WO1997042188A1 (en) 1996-05-08 1997-11-13 Kumiai Chemical Industry Co., Ltd. Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients
ES2255112T3 (es) 1996-09-12 2006-06-16 Idun Pharmaceuticals, Inc. Inhibicion de apoptosis usando inhibidores de la familia de la enzima convertidora de interleucina 1-beta (ice)/ced-3.
FR2761073B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
HUP0302477A2 (hu) 2000-10-10 2003-12-29 Smithkline Beecham Corp. Szubsztituált indolszármazékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása PPAR-gamma kötő szerként
FR2827287B1 (fr) 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
WO2007112322A2 (en) 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
MX2009006312A (es) 2006-12-14 2009-08-07 Astellas Pharma Inc Compuestos de acido policiclico utiles como antagonistas crth2 y agentes antialergicos.
US8445679B2 (en) * 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
DK2134685T3 (en) * 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
CA2746256C (en) 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
FR2961393B1 (fr) 2010-06-16 2013-02-15 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un compose indolique ou une indolinique, un sel metallique, du peroxyde d'hydrogene et un agent alcalinisant
CN103201263A (zh) 2010-09-08 2013-07-10 匹兹堡高等教育联邦体系大学 p53-Mdm2拮抗剂
EA032513B1 (ru) 2011-03-06 2019-06-28 Мерк Сероно С.А. Клеточные линии с низким содержанием фукозы и их применение
WO2013078544A1 (en) 2011-11-29 2013-06-06 Beta Pharma Canada Inc. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents
WO2013112878A1 (en) * 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
US10005728B2 (en) * 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
WO2015148854A1 (en) 2014-03-27 2015-10-01 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂

Similar Documents

Publication Publication Date Title
JP2017510641A5 (enExample)
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
CN110776507B (zh) Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN110772639B (zh) Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
JP7028809B2 (ja) コルテキソロン17α-バレレートを含む腫瘍治療に用いるための組成物
CN105163584B (zh) 用于治疗癌症的化合物
JP2019516759A5 (enExample)
JP2013529200A5 (enExample)
JP2013526540A5 (enExample)
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013529199A5 (enExample)
JP2013526538A5 (enExample)
US12312334B2 (en) Quinoxaline compounds and uses thereof
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
JP2019529475A5 (enExample)
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
CN102573833A (zh) 癌细胞凋亡
ES2779465T3 (es) Compuesto para el tratamiento o la prevención del cáncer de mama
Banik et al. Novel 6, 12-disubstituted chrysene as potent anticancer agent: synthesis, in vitro and in vivo study
BR102012028120A2 (pt) Composto derivado de ingenol, composição farmacêutica, medicamento, uso de uma ou mais derivados de ingenol e método de tratamento
TW202406903A (zh) 聯芳組成物和調控激酶級聯之方法
CN107638426B (zh) 噻唑类化合物在制备治疗肿瘤的药物中的用途
JP2020533399A (ja) 新規低分子化合物
TW201231470A (en) 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same